---
title: "Multi-step Screening and Enrichment Improves Identification of Sepsis Candidates for Prospective C"
id: "medrxiv-0-efficiency-of-a-multi-step-screening-and-enrichment-process-for-prospective"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-0-efficiency-of-a-multi-step-screening-and-enrichment-process-for-prospective"
content_type: "clinical_feed_article"
specialty: "Critical Care"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.10.07.26364969v1?rss=1"
published_at: "2026-10-09T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Multi-step Screening and Enrichment Improves Identification of Sepsis Candidates for Prospective C
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-0-efficiency-of-a-multi-step-screening-and-enrichment-process-for-prospective
- **Specialty:** [Critical Care](https://medichelpline.com/clinical-feed/critical-care.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.10.07.26364969v1?rss=1)
- **Published At:** 2026-10-09T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- The study evaluated a three-step process to identify hospitalized adults for a prospective sepsis cohort: automated **EHR** screening using **SIRS** criteria plus culture/PCR and new antibiotic, a structured chart review by trained non-physician staff (enrichment), and clinician discussion prior to enrollment. - The CISID cohort enrolled adults across ED, wards, and ICUs at a tertiary academic center; patients then underwent physician adjudication into sepsis, infection without sepsis, undifferentiated critical illness, or non-infectious sepsis mimic categories. - Between November 2023 and February 2026, 4,318 patients met automated screening; 1,220 (28%) were flagged for enrollment after the enrichment review, and 288 were ultimately enrolled. - Among enrolled patients, physician adjudication found 209 (73%) had **sepsis**, 46 (16%) infection without sepsis, 14 (5%) undifferentiated critical illness, and 19 (6.6%) non-infectious mimics. - Enrolled sepsis patients were severely ill: median **SOFA** score 9, 80% ICU admission, 48% shock; 51% were immunocompromised; in-hospital mortality 14% and 90-day mortality 27%. - In a focused 9-week sample of 907 screened encounters, the structured enrichment step increased prevalence of a composite “sepsis-likely” indicator (CDC Adult Sepsis Event criteria or ICD-10 R65.20/R65.21 within 48 hours) from 21% among deferred patients to 70% among those flagged — a 3.3-fold enrichment. - The enrichment review concentrated enrollment efforts on about one-quarter of automated-screened patients and tripled EHR-based sepsis indicators among those selected for potential enrollment. - The authors note this approach may help prospective cohorts focus limited biospecimen and longitudinal follow-up resources on patients most informative for host-response and biomarker research. - The work is a medRxiv preprint and has institutional review board approval from Mass General Brigham; it has not been peer-reviewed and should not alter clinical practice.
## Clinical Analysis & Structured Key Points
[](https://www.medrxiv.org/cdn-cgi/content?id=g5.v8j96XG6Xh18ECIIGfThjRC__wHiEqNOda5DCx3A-1791564869.3092873-1.2.1.1-ZXSl9nGjPlEzkBry7crPvaEqHbILNiTEJpEkZGeQjVSkifFyinyoGDWXfMkk5sXv) [Skip to main content](https://www.medrxiv.org/content/10.64898/2026.10.07.26364969v1?rss=1#main-content) [![medRxiv](https://www.medrxiv.org/sites/default/files/medrxiv_inner_logo.png)](https://www.medrxiv.org/) * [Home](https://www.medrxiv.org/) * [Submit](https://www.medrxiv.org/submit-a-manuscript) * [FAQ](https://www.medrxiv.org/about/FAQ) * [Blog](https://connect.medrxiv.org/news/) * [ALERTS / RSS](https://www.medrxiv.org/content/alertsrss) * [Resources](https://connect.medrxiv.org/resources/) * [About](https://www.medrxiv.org/content/about-medrxiv) Search for this keyword [Advanced Search](https://www.medrxiv.org/search) Follow this preprint # Efficiency of a Multi-step Screening and Enrichment Process for Prospective Sepsis Cohort Enrollment [ View ORCID Profile](http://orcid.org/0000-0001-7857-9145)Lisa A Cosimi, [ View ORCID Profile](http://orcid.org/0000-0002-0240-7213)Wei Qi, [ View ORCID Profile](http://orcid.org/0000-0001-9572-5933)Sarah Naz-McLean, [ View ORCID Profile](http://orcid.org/0009-0003-5838-1694)Kastin Pan, [ View ORCID Profile](http://orcid.org/0009-0003-3685-2088)Shilei Li, [ View ORCID Profile](http://orcid.org/0009-0003-7448-4714)Hannah H Laibinis, Alexis R Rooney, Con Moran, [ View ORCID Profile](http://orcid.org/0009-0008-7150-1845)Grace C Valentine, [ View ORCID Profile](http://orcid.org/0000-0003-0846-5462)Seungmin Hwang, [ View ORCID Profile](http://orcid.org/0000-0001-9218-3040)Jacques Deguine, [ View ORCID Profile](http://orcid.org/0000-0002-8763-3200)Joshua Pickard, [ View ORCID Profile](http://orcid.org/0000-0003-4262-0673)Deborah T Hung, [ View ORCID Profile](http://orcid.org/0000-0002-2810-1618)Ann E Woolley doi: https://doi.org/10.64898/2026.10.07.26364969 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Lisa A Cosimi 1 Brigham and Womens Hospital, Boston, MA USA; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Lisa%2BA%2BCosimi%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Cosimi%20LA&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ALisa%2BA%2BCosimi%2B) * [ORCID record for Lisa A Cosimi](http://orcid.org/0000-0001-7857-9145 "Open in new tab") * For correspondence: lcosimi@bwh.harvard.edu Wei Qi 2 Broad Institute of MIT and Harvard, Cambridge, MA USA * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Wei%2BQi%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Qi%20W&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AWei%2BQi%2B) * [ORCID record for Wei Qi](http://orcid.org/0000-0002-0240-7213 "Open in new tab") Sarah Naz-McLean 1 Brigham and Womens Hospital, Boston, MA USA; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Sarah%2BNaz-McLean%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Naz-McLean%20S&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ASarah%2BNaz-McLean%2B) * [ORCID record for Sarah Naz-McLean](http://orcid.org/0000-0001-9572-5933 "Open in new tab") Kastin Pan 1 Brigham and Womens Hospital, Boston, MA USA; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Kastin%2BPan%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Pan%20K&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AKastin%2BPan%2B) * [ORCID record for Kastin Pan](http://orcid.org/0009-0003-5838-1694 "Open in new tab") Shilei Li 1 Brigham and Womens Hospital, Boston, MA USA; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Shilei%2BLi%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Li%20S&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AShilei%2BLi%2B) * [ORCID record for Shilei Li](http://orcid.org/0009-0003-3685-2088 "Open in new tab") Hannah H Laibinis 1 Brigham and Womens Hospital, Boston, MA USA; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Hannah%2BH%2BLaibinis%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Laibinis%20HH&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AHannah%2BH%2BLaibinis%2B) * [ORCID record for Hannah H Laibinis](http://orcid.org/0009-0003-7448-4714 "Open in new tab") Alexis R Rooney 1 Brigham and Womens Hospital, Boston, MA USA; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Alexis%2BR%2BRooney%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Rooney%20AR&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AAlexis%2BR%2BRooney%2B) Con Moran 1 Brigham and Womens Hospital, Boston, MA USA; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Con%2BMoran%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Moran%20C&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ACon%2BMoran%2B) Grace C Valentine 1 Brigham and Womens Hospital, Boston, MA USA; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Grace%2BC%2BValentine%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Valentine%20GC&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AGrace%2BC%2BValentine%2B) * [ORCID record for Grace C Valentine](http://orcid.org/0009-0008-7150-1845 "Open in new tab") Seungmin Hwang 2 Broad Institute of MIT and Harvard, Cambridge, MA USA * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Seungmin%2BHwang%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Hwang%20S&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ASeungmin%2BHwang%2B) * [ORCID record for Seungmin Hwang](http://orcid.org/0000-0003-0846-5462 "Open in new tab") Jacques Deguine 2 Broad Institute of MIT and Harvard, Cambridge, MA USA * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Jacques%2BDeguine%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Deguine%20J&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AJacques%2BDeguine%2B) * [ORCID record for Jacques Deguine](http://orcid.org/0000-0001-9218-3040 "Open in new tab") Joshua Pickard 2 Broad Institute of MIT and Harvard, Cambridge, MA USA * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Joshua%2BPickard%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Pickard%20J&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AJoshua%2BPickard%2B) * [ORCID record for Joshua Pickard](http://orcid.org/0000-0002-8763-3200 "Open in new tab") Deborah T Hung 2 Broad Institute of MIT and Harvard, Cambridge, MA USA * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Deborah%2BT%2BHung%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Hung%20DT&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ADeborah%2BT%2BHung%2B) * [ORCID record for Deborah T Hung](http://orcid.org/0000-0003-4262-0673 "Open in new tab") Ann E Woolley 1 Brigham and Womens Hospital, Boston, MA USA; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Ann%2BE%2BWoolley%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Woolley%20AE&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AAnn%2BE%2BWoolley%2B) * [ORCID record for Ann E Woolley](http://orcid.org/0000-0002-2810-1618 "Open in new tab") * [Abstract](https://www.medrxiv.org/content/10.64898/2026.10.07.26364969v1)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_art/node:1317886/1) * [Info/History](https://www.medrxiv.org/content/10.64898/2026.10.07.26364969v1.article-info)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_info/node:1317886/1) * [Metrics](https://www.medrxiv.org/content/10.64898/2026.10.07.26364969v1.article-metrics)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_metrics/node:1317886/1) * [Supplementary material](https://www.medrxiv.org/content/10.64898/2026.10.07.26364969v1.supplementary-material)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_data/node:1317886/1) * [Data/Code](https://www.medrxiv.org/content/10.64898/2026.10.07.26364969v1.external-links)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_data_code/node:1317886/1) * [ Preview PDF](https://www.medrxiv.org/content/10.64898/2026.10.07.26364969v1.full.pdf+html)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_pdf/node:1317886/1) ![Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif) ## Abstract Background: Host response and biomarker research to advance sepsis therapeutics requires well-characterized cohorts with longitudinal biospecimens across a range of hosts and infections. Automated screening based on SIRS criteria is sensitive but nonspecific and identifies more candidates than research teams can approach, sample, and follow longitudinally. We evaluated a structured enrichment review by non-physician study staff, done after automated screening in a hospital-wide prospective sepsis cohort. Methods: The CISID cohort is a prospective observational study of hospitalized patients with suspected sepsis, enrolling adults from the ED, inpatient wards, and ICUs at a tertiary academic medical center. Patients were identified through: (1) automated electronic health record screening for two or more SIRS criteria with a 24-hour lookback, documentation of microbiologic culture or PCR, and receipt of a new antibiotic; (2) a sepsis enrichment step of structured chart review by trained non-physician study staff; and (3) discussion with the primary clinical team. Enrolled patients underwent physician adjudication into four diagnostic categories. To evaluate the enrichment step, we analyzed all patients screened during a 9-week period, assigned a composite "sepsis-likely" variable (CDC Adult Sepsis Event criteria or ICD-10 code R65.20/R65.21 within 48 hours before or after screening), and assessed mortality across each stage of screening. We also assessed concordance of the composite with physician adjudication among enrolled patients. Results: From November 2023 through February 2026, 4,318 patients screened in through EHR-based automated screening; 1,220 (28%) were flagged for enrollment, and 288 were enrolled. Physician adjudication classified 209 (73%) as sepsis, 46 (16%) as infection without sepsis, 14 (5%) were classified as undifferentiated critical illness, and 19 (6.6%) as non-infectious sepsis mimics. Patients with sepsis were severely ill (median SOFA score, 9; ICU admission, 80%; shock, 48%), and 51% were immunocompromised; mortality was 14% in hospital and 27% at 90 days. In a 9-week sample of 907 screened encounters, 21% of those deferred and 70% of those flagged for enrollment met the sepsis-likely composite, a 3.3-fold increase in prevalence after structured study team review. Conclusions: A brief structured enrichment review after automated screening tripled the prevalence of EHR-based sepsis indicators among patients selected for enrollment, while concentrating enrollment efforts on roughly one-quarter of screened-in patients in this hospital-wide, all-source suspected-sepsis cohort. This approach may help prospective cohorts direct limited biospecimen resources toward patients most informative for host-response and biomarker research. ### Competing Interest Statement The authors have declared no competing interest. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The institutional review board of Mass General Brigham gave ethical approval for this work I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes ## Data Availability All data produced in the present work are contained in the manuscript Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC 4.0 International license](http://creativecommons.org/licenses/by-nc/4.0/). bioRxiv and medRxiv thank the following for their generous financial support: > The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam. [Donate to openRxiv ](https://www.zeffy.com/en-US/donation-form/donate-to-make-a-difference-10981) [ Back to top](https://www.medrxiv.org/content/10.64898/2026.10.07.26364969v1?rss=1#page) [ Previous](https://www.medrxiv.org/content/10.64898/2026.10.04.26364685v2 "Which Features of Medication Double-Check Procedures are Considered Desirable and Implemented in Practice? A Cross-Sectional Web-Based Vignette Study among Nurses in Japan") Posted October 09, 2026. [ Download PDF](https://www.medrxiv.org/content/10.64898/2026.10.07.26364969v1.full.pdf) Print/Save Options [Download PDF](https://www.medrxiv.org/content/medrxiv/early/2026/10/09/2026.10.07.26364969.full.pdf)Full Text & In-line FiguresXML [More Info](https://www.medrxiv.org/about/FAQ#PrintOptions "More Information on Print/Save Options") [ Author Declarations](https://www.medrxiv.org/content/10.64898/2026.10.07.26364969v1#p-5) [Supplementary Material ](https://www.medrxiv.org/content/10.64898/2026.10.07.26364969v1.supplementary-material) [ Data/Code](https://www.medrxiv.org/content/early/2026/10/09/2026.10.07.26364969.external-links) [ Email](https://www.medrxiv.org/ "Email this Article") [ Share](https://www.medrxiv.org/) Efficiency of a Multi-step Screening and Enrichment Process for Prospective Sepsis Cohort Enrollment Lisa A Cosimi, Wei Qi, Sarah Naz-McLean, Kastin Pan, Shilei Li, Hannah H Laibinis, Alexis R Rooney, Con Moran, Grace C Valentine, Seungmin Hwang, Jacques Deguine, Joshua Pickard, Deborah T Hung, Ann E Woolley medRxiv 2026.10.07.26364969; doi: https://doi.org/10.64898/2026.10.07.26364969 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Share This Article: Copy [![Twitter logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/twitter.png)](https://www.medrxiv.org/highwire_log/share/twitter?link=http%3A%2F%2Ftwitter.com%2Fshare%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.10.07.26364969v1%26text%3DEfficiency%2520of%2520a%2520Multi-step%2520Screening%2520and%2520Enrichment%2520Process%2520for%2520Prospective%2520Sepsis%2520Cohort%2520Enrollment "Share this on Twitter") [![Facebook logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/fb-blue.png)](https://www.medrxiv.org/highwire_log/share/facebook?link=http%3A%2F%2Fwww.facebook.com%2Fsharer.php%3Fu%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.10.07.26364969v1%26t%3DEfficiency%2520of%2520a%2520Multi-step%2520Screening%2520and%2520Enrichment%2520Process%2520for%2520Prospective%2520Sepsis%2520Cohort%2520Enrollment "Share on Facebook") [![LinkedIn logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/linkedin-32px.png)](https://www.medrxiv.org/highwire_log/share/linkedin?link=http%3A%2F%2Fwww.linkedin.com%2FshareArticle%3Fmini%3Dtrue%26url%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.10.07.26364969v1%26title%3DEfficiency%2520of%2520a%2520Multi-step%2520Screening%2520and%2520Enrichment%2520Process%2520for%2520Prospective%2520Sepsis%2520Cohort%2520Enrollment%26summary%3D%26source%3DmedRxiv "Publish this post to LinkedIn") [![Mendeley logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/mendeley.png)](https://www.medrxiv.org/highwi
## Related Clinical Research

- [Fully automated sample-to-answer system for rapid molecular detection of pathogens in whole blood](https://medichelpline.com/clinical-feed/pubmed-42648850.md) (DOI: 10.1016/j.aca.2026.345980)
- [Proenkephalin A Predicts Hydrocortisone Effect on Kidney Outcomes in Septic Shock (VANISH Post Hoc)](https://medichelpline.com/clinical-feed/pubmed-42902572.md) (DOI: 10.1097/CCE.0000000000001496)
- [Early Post-Insertion PaO2 and Upper-Body Venous Thrombosis Risk in Critically Ill Adults](https://medichelpline.com/clinical-feed/plos-one-17-association-between-early-post-insertion-arterial-oxygen-tension-and-documented.md)
- [Evaluating Community-Acquired Acute Infections in Irish Emergency Departments](https://medichelpline.com/clinical-feed/plos-one-2-assessing-community-acquired-acute-infection-in-an-irish-emergency-department-a.md)
- [Single-timepoint inflammatory protein panel poorly separates sepsis from sepsis mimics](https://medichelpline.com/clinical-feed/medrxiv-3-inflammatory-protein-profiling-shows-limited-ability-to-distinguish-sepsis-from.md)

## Navigation
- [← Back to Critical Care Feed](https://medichelpline.com/clinical-feed/critical-care.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.